Congress meeting · Dr. Ulrich Hayashi

03 Feb 2026 · Virtual · Dr. Ulrich Hayashi, Christie NHS Foundation Trust · MSL Dr. Anna Becker · Nephrada

ReviewedVeeva CRMENG-0133—

Capture insight from this engagement

Location: Christie NHS Foundation Trust
Therapeutic area: Nephrology
Country: United Kingdom
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

APRIL pathway mechanism
Treatment burden and fatigue
eGFR slope interpretation

Scientific content used

NPH mechanism-of-action deck
APRIL-IgAN Phase III topline

Questions raised

What is the immunoglobulin monitoring recommendation?
How does proteinuria reduction at 9 months translate to eGFR benefit?

Notes

Congress meeting with renal pathologist at Christie NHS Foundation Trust. Discussed april pathway mechanism, treatment burden and fatigue, egfr slope interpretation.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Connect with Clinical Development

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 5
Depth of exchange: 1
Actionability: 2

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0133

Audit history (0)

All create, update and approval events for this record

No audit events in sample data